Artiva Biotherapeutics, Inc.

NasdaqGM:ARTV Stock Report

Market Cap: US$48.7m

Artiva Biotherapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Fred Aslan

Chief executive officer

US$7.8m

Total compensation

CEO salary percentage7.94%
CEO tenure4.3yrs
CEO ownershipn/a
Management average tenure1.3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Will Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely?

Jan 20
Will Artiva Biotherapeutics (NASDAQ:ARTV) Spend Its Cash Wisely?

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22

CEO Compensation Analysis

How has Fred Aslan's remuneration changed compared to Artiva Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$72m

Dec 31 2024US$8mUS$622k

-US$65m

Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$33m

Mar 31 2024n/an/a

-US$26m

Dec 31 2023US$1mUS$584k

-US$29m

Mar 31 2023n/an/a

-US$63m

Dec 31 2022n/an/a

-US$59m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$3mUS$480k

-US$72m

Compensation vs Market: Fred's total compensation ($USD7.83M) is above average for companies of similar size in the US market ($USD645.28K).

Compensation vs Earnings: Fred's compensation has increased whilst the company is unprofitable.

CEO

Fred Aslan (49 yo)

4.3yrs
Tenure
US$7,827,554
Compensation

Dr. Fred Aslan, M.D. is Founder of Adavium Medical, Inc. and serves as its Director. Dr. Aslan serves as President, Chief Executive Officer and Director at Artiva Biotherapeutics, Inc. since January 2021....

Leadership Team

NamePositionTenureCompensationOwnership
Fred Aslan
President4.3yrsUS$7.83mno data
Neha Krishnamohan
CFO & Executive VP of Corporate Development1.1yrsUS$2.29m0%
$ 0
Jennifer Bush
Executive VP4.7yrsUS$1.51m0.094%
$ 45.6k
Peter Flynn
Co-Founder & Strategic Advisorno dataUS$762.47k0.16%
$ 79.8k
Christopher Horan
Chief Technical Operations Officer3.4yrsUS$726.90k0%
$ 0
Heather Raymon
Senior Vice President of Research & Early Development2.3yrsno datano data
David Moriarty
Senior VP of Clinical Operations1.3yrsno datano data
Benjamin Dewees
Senior Vice President of Regulatory Affairsless than a yearno datano data
Feng Xu
Senior Vice President of Biometricsless than a yearno datano data
Subhashis Banerjee
Chief Medical Officerless than a yearno datano data
1.3yrs
Average Tenure
50yo
Average Age

Experienced Management: ARTV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Fred Aslan
President4.3yrsUS$7.83mno data
Peter Flynn
Co-Founder & Strategic Advisorno dataUS$762.47k0.16%
$ 79.8k
Elizabeth Hougen
Independent Director4.1yrsUS$87.30k0%
$ 0
Richard Maziarz
Advisorno datano datano data
Kenneth Kalunian
Advisorno datano datano data
Jill Buyon
Advisorno datano datano data
Brian Daniels
Independent Chairman of the Board4.9yrsUS$42.74kno data
Yong-Jun Huh
Director5.7yrsno datano data
Brad Rovin
Advisorno datano datano data
Laura Stoppel
Independent Director4.9yrsUS$22.61kno data
Laura Bessen
Independent Director3.2yrsUS$78.38k0%
$ 0
Thorsten Graef
Strategic Advisorless than a yearno datano data
4.3yrs
Average Tenure
50yo
Average Age

Experienced Board: ARTV's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 00:17
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Artiva Biotherapeutics, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Edward WhiteH.C. Wainwright & Co.
Dingding ShiJefferies LLC